Status and phase
Conditions
Treatments
About
This first-in-human clinical trial with a randomized, double-blind, placebo-controlled, dose-escalation study design is regarded as standard to test the safety, tolerability, and pharmacokinetics of KYN-5356.
The study comprises 3 parts:
Part 1: Single Ascending Dose study Part 2: Multiple Ascending Dose study Part 3: Food Effect study
The aim of Parts 1 and 2 of the study is to evaluate the safety and tolerability following single and multiple ascending doses of KYN-5356.
The secondary aim is to evaluate the pharmacokinetics (PK) of escalating single and multiple doses of KYN-5356. In Part 2, cerebrospinal fluid will be sampled to explore PK and pharmacodynamic effects of KYN-5356.
The potential effect of food intake on the disposition of KYN-5356 following a single oral dose will be evaluated in Part 3. Part 3 is an open-label, randomized, 2 period, 2 sequence design.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
80 participants in 10 patient groups
Loading...
Central trial contact
Hakop Gevorkyan, MD, MBA
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal